Follow-up data on 97 of the 101 patients at a university-based psychia
tric hospital for whom risperidone had been prescribed between Februar
y 1994, when the medication was introduced, and October 1996 were revi
ewed an average of 102, weeks after the start of the medication. Only
28.9 percent of the patients were still on risperidone at follow-up. P
atients who were maintained on risperidone were able to tolerate a hig
her close with fewer side effects. The most common reasons for discont
inuation were failure to achieve a therapeutic effect, noncompliance,
and adverse side effects. The findings of this naturalistic study repr
esent a cautionary consideration for the remarkable enthusiasm that su
rrounded the introduction of risperidone.